Predictors Affecting Long-term Use of Solifenacin or Mirabegron in Women With Overactive Bladder Syndrome

Last updated: March 27, 2023
Sponsor: Far Eastern Memorial Hospital
Overall Status: Active - Recruiting

Phase

N/A

Condition

Interstitial Cystitis

Treatment

N/A

Clinical Study ID

NCT05040984
110053-E
  • Ages > 20
  • Female

Study Summary

A retrospective analysis of medical records at Far Eastern Memorial Hospital from January 2008 to May 2020 about female patients with overactive bladder syndrome, who received Solifenacin or Mirabegron as the initial treatment. Factors affecting persistence of OAB medications will be analyzed.

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Women with overactive bladder syndrome received solifenacin or mirabegron as theinitial treatment

Exclusion

Exclusion Criteria:

  • <20 year-old

Study Design

Total Participants: 500
Study Start date:
April 30, 2021
Estimated Completion Date:
December 31, 2024

Connect with a study center

  • Department of Obstetrics and Gynecology, Far-Eastern Memorial Hospital

    Banqiao, New Taipei 22050
    Taiwan

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.